Pharmaceutical giant AstraZeneca writes $440m cheque for UCL spin-out Spirogen.
Spirogen, a life sciences spin-out of University College London, has been acquired by pharmaceutical conglomerate AstraZeneca for $440m. The trade sale, made through AZ subsidiary MedImmune, will see AstraZeneca pay $200m up front in cash with a further $240m in return for the firm achieving developmental milestones. Spirogen is developing cancer-fighting technology known as proprietary…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
